Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Edo-S101, a Bendamustine (BDM)/ Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Demonstrates Potent Preclinical Activity Against T-Cell Malignancies and Overcomes BDM-Resistance

Rosaria De Filippi, MD PhD, Stefania Crisci, ScD, Sara Mele, BS, Serena Zanotta, ScD, Gaetano Corazzelli, MD, Domenico Galati, MD PhD, Davide Coppola, RN, Piera Maiolino, PharmD, Mariangela Saggese, PharmD, Francesco Volzone, MD, Emanuela Morelli, MD, Daniela Donnarumma, MD, Gianpaolo Marcacci, MD, Ferdinando Frigeri, MD, Niels Odum, MD, Thomas Mehrling, MD PhD, Antonio Pinto, MD

Blood (2017) 130 (Supplement 1): 2547.

https://doi.org/10.1182/blood.V130.Suppl_1.2547.2547

Published: 2017

Journal Articles

The First in Class, Alkylator-Histone-Deacetylase-Inhibitor Fusion Molecule Edo-S101 in Combination with Proteasome Inhibitors Induces Highly Synergistic Pro-Apoptotic Signaling through UPR Activation and Suppression of c-Myc and BCL2 in Multiple Myeloma

Lenka Besse, PhD, Marianne Kraus, PhD, Andrej Besse, Juergen Bader, Thomas Mehrling, MD PhD, Christoph Driessen, MD PhD

Blood (2016) 128 (22): 4466.

https://doi.org/10.1182/blood.V128.22.4466.4466

Published: 2016

Journal Articles

The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones

Rosaria De Filippi, MD PhD, Stefania Crisci, ScD, Michele Cillo, ScD, Sara Mele, BS, Angela De Monaco, ScD, Domenico Galati, MD, Serena Zanotta, ScD, Gaetana Capobianco, MD, Francesco Volzone, MD, Manuela Arcamone, MD, Piera Maiolino, PharmD, Mariangela Saggese, PharmD, Gaetano Corazzelli, MD, Ferdinando Frigeri, MD PhD, Thomas Mehrling, MD PhD, Antonello Pinto, MD

Blood (2015) 126 (23): 2481.

https://doi.org/10.1182/blood.V126.23.2481.2481

Published: 2015

Journal Articles

The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone

Ana Alicia López-Iglesias, Ana Belen Herrero, Laura San-Segundo, Susana Hernández-García, Lorena González-Méndez, Montserrat Martín-Sánchez, Esperanza M Algarín, Teresa Paino, Mercedes Garayoa, Thomas Mehrling, MD PhD, Norma C Gutierrez, Jesús F. San-Miguel, MD, Maria-Victoria Mateos, Enrique M. Ocio, MD PhD

Blood (2015) 126 (23): 5354.

https://doi.org/10.1182/blood.V126.23.5354.5354

Published: 2015

Journal Articles

The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies

Ana Alicia López-Iglesias, MD, Laura San-Segundo, Lorena González-Méndez, Susana Hernández-García, Daniel Primo, PhD, Mercedes Garayoa, PhD BS, Ana Belén Hernández, PhD, Teresa Paíno, PhD, Maria-Victoria Mateos, MD PhD, Yi Chen, Enrique M. Ocio, MD PhD, Thomas Mehrling, MD PhD

Blood (2014) 124 (21): 2100.

https://doi.org/10.1182/blood.V124.21.2100.2100

Published: 2014

Journal Articles

Edo- S101, a New Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Has Superior Activity Against Myeloma and B Cell Lymphoma and Strong Synergy with Proteasome Inhibitors in Vitro

Marianne Kraus, PhD, Jürgen Bader, Thomas Mehrling, MD PhD, Christoph Driessen, MD

Blood (2014) 124 (21): 2249.

https://doi.org/10.1182/blood.V124.21.2249.2249

Published: 2014

NARROW

Edo-S101, a Bendamustine (BDM)/ Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Demonstrates Potent Preclinical Activity Against T-Cell Malignancies and Overcomes BDM-Resistance

The First in Class, Alkylator-Histone-Deacetylase-Inhibitor Fusion Molecule Edo-S101 in Combination with Proteasome Inhibitors Induces Highly Synergistic Pro-Apoptotic Signaling through UPR Activation and Suppression of c-Myc and BCL2 in Multiple Myeloma

The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones

The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone

The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies

Edo- S101, a New Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Has Superior Activity Against Myeloma and B Cell Lymphoma and Strong Synergy with Proteasome Inhibitors in Vitro

Email alerts

ASH Publications

American Society of Hematology

Edo-S101, a Bendamustine (BDM)/ Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Demonstrates Potent Preclinical Activity Against T-Cell Malignancies and Overcomes BDM-Resistance

The First in Class, Alkylator-Histone-Deacetylase-Inhibitor Fusion Molecule Edo-S101 in Combination with Proteasome Inhibitors Induces Highly Synergistic Pro-Apoptotic Signaling through UPR Activation and Suppression of c-Myc and BCL2 in Multiple Myeloma

The First-in-Class Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule Edo-S101 Exerts Potent Preclinical Activity Against Tumor Cells of Hodgkin Lymphoma (HL) Including Bendamustine-Resistant Clones

The Hybrid Molecule, Edo-S101, Impairs Double Strand Breaks Repair in Multiple Myeloma and Synergizes with Bortezomib and Dexamethasone

The Alkylating Histone Deacetylase Inhibitor Fusion Molecule Edo-S101 Displays Full Bi-Functional Properties in Preclinical Models of Hematological Malignancies

Edo- S101, a New Alkylating Histone-Deacetylase Inhibitor (HDACi) Fusion Molecule, Has Superior Activity Against Myeloma and B Cell Lymphoma and Strong Synergy with Proteasome Inhibitors in Vitro

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only